A randomized, open-label, 2-stage study of INCB047986 administered orally to subjects with primary myelodysplastic syndrome (MDS) refractory to or unlikely to respond to erythropoiesis-stimulating agents (ESAs)

Trial Profile

A randomized, open-label, 2-stage study of INCB047986 administered orally to subjects with primary myelodysplastic syndrome (MDS) refractory to or unlikely to respond to erythropoiesis-stimulating agents (ESAs)

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs INCB 47986 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 22 Feb 2015 Status changed from active, no longer recruiting to suspended as per ClinicalTrials.gov record.
    • 02 Sep 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 03 Jun 2014 New source identified and integrated (Oregon Health and Science University).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top